Nevertheless, further development of Podxl core protein-binding antibodies as cancer immunotherapeutics has been hampered by concerns over possible toxicity to normal vascular and renal tissue where Podxl is abundantly expressed in healthy adults. Here, PODXL is linked to cancer.